Summary of BridgeBio Pharma FY Conference Call Company Overview - **Company**: BridgeBio Pharma (NasdaqGS:BBIO) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **CEO**: Neil Kumar Key Points Company Milestones - BridgeBio celebrates its 10th anniversary, having developed a highly efficient R&D engine for genetic diseases with three approved products and three more expected in the next 12 months [2][3] - Nearly 20 Investigational New Drug (IND) applications generated, impacting approximately 10,000 patient lives [3] Financial Performance - Q4 revenue pre-announced at **$146 million**, representing a **35% growth** from the previous quarter and suggesting a **60% compound annual growth rate (CAGR)** [4] - Total revenue for the first four quarters reached **$362 million** [5] - The company aims for a **30%-35% peak year market share** by volume for its product Attruby, with over **25% market share** achieved in the first year [5] Product Updates ATTR Cardiomyopathy - Attruby is the first and only near-complete stabilizer approved by the FDA, showing a **42% relative risk reduction** in all-cause mortality and cardiovascular hospitalization at 30 months [6] - Over **50 publications** and abstracts have been released regarding the drug's efficacy and patient population performance [6] Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) - Interim phase three results showed a **1.8 times increase** in glycosylation of the alpha-dystroglycan complex and an **82% decrease** in muscle damage [15] - Statistically significant improvements in ambulation and breathing were observed, indicating potential therapeutic cures for some patients [16] ADH1 - Phase 3 results indicated a **76% responder rate** for normalization of urine and serum calcium levels, significantly outperforming the standard of care [20] - The company has identified **1,700 unique patients** with ADH1 through improved genetic testing and updated guidelines [24] Chronic Hypoparathyroidism - A trial showed **80% normalization** of urine and serum calcium levels, with plans to initiate the Reclaim HP trial mid-year [26] Achondroplasia and Hypochondroplasia - The company is advancing its small molecule program targeting FGFR3 over-activation, with phase three data expected in Q1 [28][29] Canavan Disease - A gene therapy approach is being developed, with a BLA filing anticipated in 2027 [36] Market Strategy - The company employs a decentralized model for product launches, leveraging existing infrastructure to minimize costs [37] - Market research indicates a potential **52% market share** for its new products based on favorable profiles compared to existing treatments [34] Future Outlook - BridgeBio emphasizes that it is still "day one" in the era of genetic medicine, with ongoing advancements in genetic research and therapeutic development [38][39] - The company is focused on identifying new patient populations and expanding its pipeline, with **17 early-stage programs** in development at Gondola Bio [40] Conclusion - BridgeBio is well-financed and positioned for significant growth, aiming to serve more patients with innovative therapies in the coming years [48]

Core Viewpoint - H.C. Wainwright reiterated a Neutral rating and $11 price target on Biohaven Pharmaceutical Holding Co. following disappointing clinical results for BHV-7000 in major depressive disorder [1] Group 1: Clinical Trial Results - The study for BHV-7000 failed to meet its primary endpoint of improvement in MADRS scores over six weeks compared to placebo [3] - Secondary endpoints, including CGI-S and SHAPS, were also missed in the trial [3] - Biohaven plans to conduct additional subgroup analyses, but these will be exploratory only, with no further trials planned for the program [3] Group 2: Market Focus and Future Directions - Investor attention has largely shifted to the upcoming focal onset seizure readout, with some investors hoping for positive MDD data as a catalyst [2] - Biohaven intends to redirect focus toward priority areas in 2026, including immunology, obesity, and epilepsy [4] - The results of BHV-7000 did not materially affect expectations for Xenon Pharmaceuticals' azetukalner Phase 3 MDD program [4]

Group 1 - There are investment opportunities in biotech companies with lead products that have undergone extensive mid-stage development and long-term testing through open-label extension trials [1] - The focus is on high-growth companies in sectors expected to experience exponential expansion, particularly those involved in disruptive technologies [1] - The investment approach combines fundamental analysis with predictions of future trends, emphasizing the potential of innovation to generate significant returns [1]

Core Viewpoint - The investor webinar focuses on Xenon Pharmaceuticals' Kv7 and Nav1.7 programs aimed at pain treatment, highlighting the company's leadership in ion channel drug development [1][4]. Company Overview - Ian Mortimer serves as the President and CEO of Xenon Pharmaceuticals and is moderating the session [1]. - The company has a strong pipeline and a history of positioning itself as a leader in ion channel drug development [4]. Key Personnel - Dr. Jim Empfield, Executive Vice President of Drug Discovery, will discuss Xenon's history and its advancements in drug development [3][4]. - Dr. JP Gilbert, Senior Director of Biology, and Dr. Chris Kenney, Chief Medical Officer, are also part of the speaking team [3].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Views - The pharmaceutical sector is expected to experience positive growth factors in 2025, driven by innovation, international expansion, and an aging population [4][5] - The report highlights the significant unmet demand for new drugs in the epilepsy and depression markets, suggesting potential investment opportunities in companies like Hainan Haiyao and Warner Pharmaceuticals [3][4] Summary by Sections Epilepsy Market Potential - Approximately 9 million epilepsy patients in China, with about 30% unresponsive to current treatments, indicating a substantial market opportunity [10][11] - The anti-epileptic drug market in China is projected to exceed 10 billion yuan, with significant growth potential for innovative drugs targeting KCNQ channels [4][10][12] Depression Treatment Demand - Depression poses a major public health threat, with a global market for antidepressants expected to reach $17.6 billion by 2030 [39] - The report emphasizes the urgent need for rapid-acting and effective treatments for major depressive disorder with suicidal ideation (MDSI), highlighting the limitations of traditional antidepressants [41][43] Key Companies and Products - Warner Pharmaceuticals' ZG001, a modified version of ketamine, shows promise in treating depression without addiction risks, currently in clinical trials [47] - Johnson & Johnson's Spravato (esketamine) is the only approved treatment for MDSI, with projected sales reaching $3 billion by 2027 [44][45] Industry Trends - The report notes a successful transition from generic to innovative drug development in China, with companies like Heng Rui Medicine and Kelun Pharmaceutical leading the way [5] - The aging population is driving demand for treatments related to chronic diseases, further enhancing the growth prospects for the pharmaceutical sector [5]

Core Viewpoint - Xenon Pharmaceuticals reported a narrower loss per share for Q4 2024 compared to the previous year, but did not generate any revenues due to the absence of marketed products [1][2][8] Financial Performance - The company reported a loss of 84 cents per share in Q4 2024, which is an improvement from a loss of 64 cents per share in the same quarter last year [1] - For the full year 2024, Xenon recorded a loss per share of $3.01, which is narrower than the Zacks Consensus Estimate of a loss of $3.10 [8] - Research and development (R&D) expenses increased by 45% to $59.5 million in Q4 2024, up from $41.1 million in the prior year [5] - General and administrative expenses rose by 43% year over year to $18 million, driven by higher personnel costs and consulting fees [6] Revenue Generation - Xenon did not recognize any revenues in Q4 2024 or in the year-ago quarter, primarily due to the lack of marketed products [2][8] - The company has ongoing collaboration revenues from its partnership with Neurocrine Biosciences for NBI-921352, but no revenues were recognized from this collaboration in the reported quarter [2][3] Pipeline Development - Xenon is developing azetukalner for treating focal onset seizures and has initiated phase III studies, with top-line data expected in the second half of 2025 [10] - The company is also evaluating azetukalner for primary generalized tonic-clonic seizures and has plans for a late-stage bipolar depression program [12][14] - A phase II proof-of-concept study for azetukalner in major depressive disorder (MDD) has been completed, leading to the initiation of phase III studies [13][15] - The company is collaborating with the Icahn School of Medicine for an ongoing phase II study of azetukalner in MDD [15] Cash Position - As of December 31, 2024, Xenon had cash, cash equivalents, and marketable securities totaling $754.4 million, down from $803.3 million as of September 30, 2024 [7] - The company expects its cash balance to support its operating plans through 2027, including ongoing clinical studies [7]